Evidence map›Paper›PMID 37525235›Full record

ArticleSystematic reviews2023

Clinical utility of overviews on adverse events of pharmacological interventions.

Thilo Sachse, Salmaan Kanji, Pierre Thabet, Sven Schmiedl, Petra Thürmann, Fadi Guirguis, Shellyza Sajwani, Marie-France Gauthier, Carole Lunny, Tim Mathes and 1 more

Abstract read
In one paragraph

Article in Systematic reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Thilo SachseFaculty of Health, School of Medicine, Institute for Research in Operative Medicine, Witten/Herdecke University, 51109, Cologne, Germany. thilo.sachse@uni-wh.de.ORCID 0000-0001-9625-9858
Salmaan KanjiThe Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Pierre ThabetHôpital Montfort and University of Ottawa, Ottawa, Ontario, Canada.
Sven SchmiedlPhilipp Klee-Institute of Clinical Pharmacology, Helios University Hospital Wuppertal, Witten/Herdecke University, Chair of Clinical Pharmacology, Wuppertal, Germany.
Petra ThürmannPhilipp Klee-Institute of Clinical Pharmacology, Helios University Hospital Wuppertal, Witten/Herdecke University, Chair of Clinical Pharmacology, Wuppertal, Germany.
Fadi GuirguisThe Ottawa Hospital, Ottawa, Ontario, Canada.
Shellyza SajwaniThe Ottawa Hospital, Ottawa, Ontario, Canada.
Marie-France GauthierHôpital Montfort and University of Ottawa, Ottawa, Ontario, Canada.
Carole LunnyKnowledge Translation Program, Unity Health Toronto and the Cochrane Hypertension Group, St. Michael's Hospital, University of British Columbia, Vancouver, Canada.
Tim MathesFaculty of Health, School of Medicine, Institute for Research in Operative Medicine, Witten/Herdecke University, 51109, Cologne, Germany.
Dawid PieperFaculty of Health, School of Medicine, Institute for Research in Operative Medicine, Witten/Herdecke University, 51109, Cologne, Germany.

Funding

CIHR
6 · The paper itself

Abstract

backgroundOverviews (i.e., systematic reviews of systematic reviews, meta-reviews, umbrella reviews) are a relatively new type of evidence synthesis. Among others, one reason to conduct an overview is to investigate adverse events (AEs) associated with a healthcare intervention. Overviews aim to provide easily accessible information for healthcare decision-makers including clinicians. We aimed to evaluate the clinical utility of overviews investigating AEs.

methodsWe used a sample of 27 overviews exclusively investigating drug-related adverse events published until 2021 identified in a prior project. We defined clinical utility as the extent to which overviews are perceived to be useful in clinical practice. Each included overview was assigned to one of seven pharmacological experts with expertise on the topic of the overview. The clinical utility and value of these overviews were determined using a self-developed assessment tool. This included four open-ended questions and a ranking of three clinical utility statements completed by clinicians. We calculated frequencies for the ranked clinical utility statements and coded the answers to the open-ended questions using an inductive approach.

resultsThe overall agreement with the provided statements was high. According to the assessments, 67% of the included overviews generated new knowledge. In 93% of the assessments, the overviews were found to add value to the existing literature. The overviews were rated as more useful than the individual included systematic reviews (SRs) in 85% of the assessments. The answers to the open-ended questions revealed two key aspects of clinical utility in the included overviews. Firstly, it was considered useful that they provide a summary of available evidence (e.g., along with additional assessments, or across different populations, or in different settings that have not been evaluated together in the included SRs). Secondly, it was found useful if overviews conducted a new meta-analysis to answer specific research questions that had not been answered previously.

conclusionsOverviews on drug-related AEs are considered valuable for clinical practice by clinicians. They can make available evidence on AEs more accessible and provide a comprehensive view of available evidence. As the role of overviews evolves, investigations such as this can identify areas of value.

Indexed as

Delivery of Health CarePublicationsHealth FacilitiesHumansSystematic Reviews as TopicAdverse eventsClinical utilityEvidence synthesisMeta-reviewsOverviewsPharmacology

Identifiers

PMID37525235
PMCPMC10388527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.